Mark Fishman: The critical challenge is scientific

Novartis and Stem Cells

February 2009. What value does Novartis attach to its stem cell patents? Mark Fishman, President of the Novartis Institutes for BioMedical Research comments his company’s strategy and technology acquisitions in the field.Reading time: 1 min

Read Now:
1,00 EUR (incl. 7% VAT)

Back to section